RT Journal Article
SR Electronic
T1 The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.122.264031
DO 10.2967/jnumed.122.264031
A1 Anne M Smith
A1 Nancy A. Obuchowski
A1 Norman L Foster
A1 Gregory Klein
A1 P. David Mozley
A1 Adriaan A. Lammertsma
A1 Richard L. Wahl
A1 John Sunderland
A1 Jean-Luc E Vanderheyden
A1 Tammie L.S. Benzinger
A1 Paul E. Kinahan
A1 Dean F. Wong
A1 Eric S. Perlman
A1 Satoshi Minoshima
A1 Dawn Matthews
YR 2022
UL http://jnm.snmjournals.org/content/early/2022/09/22/jnumed.122.264031.abstract
AB A standardized approach to acquiring amyloid PET images increases their value as disease and drug response biomarkers. The majority of 18F PET amyloid brain scans often are assessed only visually (per regulatory labels), with a binary decision indicating the presence or absence of Alzheimer’s disease amyloid pathology. Minimizing technical variance allows precise, quantitative, standardized uptake value ratios (SUVRs) for early detection of a𝛽 amyloid plaques and the effectiveness of anti-amyloid treatments to be assessed with serial studies. Methods: The Quantitative Imaging Biomarkers Alliance (QIBA) Amyloid PET Biomarker Committee developed and validated a Profile to characterize and reduce the variability of SUVRs, increasing statistical power for these assessments. Results: Upon achieving conformance, sites can justify a claim that brain amyloid burden reflected by the SUVR is measurable to a within-subject coefficient of variation (wCV) of ≤1.94% when the same radiopharmaceutical, scanner, acquisition and analysis protocols are used. Conclusion: This overview explains the claim, requirements, barriers and potential future developments of the Profile to achieve precision in clinical and research amyloid PET imaging.